BrainsWay’s Accelerated Deep TMS Coverage Expands to 57M Lives
Event summary
- BrainsWay’s SWIFT Accelerated Deep TMS™ protocol now covers over 57 million lives across eight major payers and the US Department of Veterans Affairs.
- Latest policy change in South Carolina adds 2 million members to covered lives, expanding access for MDD and OCD patients.
- CEO Hadar Levy cites growing clinical evidence supporting efficacy and durability of Deep TMS therapies as key driver of adoption.
The big picture
BrainsWay’s expansion in favorable coverage for its Accelerated Deep TMS™ protocol reflects broader industry trends toward non-invasive neurostimulation treatments gaining traction. The company’s proprietary H-coil technology and robust clinical research position it as a leader in mental health innovation, though sustained growth will depend on maintaining reimbursement momentum and differentiating from emerging competitors.
What we're watching
- Clinical Validation
- How the growing body of clinical evidence will further accelerate payer adoption and reimbursement policies.
- Market Expansion
- Whether BrainsWay can sustain this momentum in securing favorable coverage across additional US states and international markets.
- Competitive Dynamics
- The pace at which competitors develop similar accelerated TMS protocols, potentially challenging BrainsWay’s market leadership.
Related topics